Prevalence of disease-modifying drug treatment gaps in patients with multiple sclerosis

被引：0
|
作者：
Joyeux, A.
Kozma, C.
Meletiche, D.
Dickson, M.
Bennett, R.
机构：
[1] Merck Serono, Geneva, Switzerland
[2] Univ S Carolina, Columbia, SC 29208 USA
[3] EMD Serono Inc, Rockland, ME USA
来源：
JOURNAL OF NEUROLOGY | 2009年 / 256卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S163 / S163
页数：1
相关论文
共 50 条
  • [21] Disease-modifying therapies for multiple sclerosis
    John R. Corboy
    Douglas S. Goodin
    Elliot M. Frohman
    [J]. Current Treatment Options in Neurology, 2003, 5 (1) : 35 - 54
  • [22] Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis
    Vartanian, TK
    Zamvil, SS
    Fox, E
    Sorensen, PS
    [J]. NEUROLOGY, 2004, 63 (11) : S42 - S49
  • [23] Association of Timing of Disease-Modifying Drug Treatment Initiation on Multiple Sclerosis Relapse Rates in Newly Diagnosed Patients
    Phillips, Amy
    Fang, Juanzhi
    Corvino, Frank
    Oliveri, David
    [J]. NEUROLOGY, 2016, 86
  • [24] Factors associated with early initiation of disease-modifying drug treatment in newly-diagnosed patients with multiple sclerosis
    Edwards, Natalie C.
    Munsell, Michael
    Menzim, Joseph
    Phillips, Amy L.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (08) : 1389 - 1395
  • [25] Commentary Adverse Drug Reactions of Multiple Sclerosis Disease-modifying Drugs
    Salehbayat, Maryam
    Abolfazli, Roya
    Mohebbi, Niayesh
    Savar, Seyed Mehrdad
    Shalviri, Gloria
    Gholami, Kheirollah
    [J]. BASIC AND CLINICAL NEUROSCIENCE, 2023, 14 (06) : 879 - 884
  • [26] Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain
    Morillo Verdugo, Ramon
    Ramirez Herraiz, Esther
    Fernandez-Del Olmo, Raquel
    Roig Bonet, Montserrat
    Valdivia Garcia, Maria
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2019, 13 : 261 - 272
  • [27] Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies
    Grebenciucova, Elena
    Pruitt, Amy
    [J]. CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2017, 17 (11)
  • [28] Infections in patients with multiple sclerosis: Implications for disease-modifying therapy
    Celius, E. G.
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 2017, 136 : 34 - 36
  • [29] FIRST USE OF DISEASE-MODIFYING DRUGS IN PATIENTS WITH MULTIPLE SCLEROSIS
    Meletiche, D. M.
    Kozma, C.
    Dickson, M.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A193 - A193
  • [30] Persistence to oral disease-modifying therapies in multiple sclerosis patients
    Simona Lattanzi
    Maura Danni
    Ruja Taffi
    Raffaella Cerqua
    Giulia Carlini
    Alessandra Pulcini
    Leandro Provinciali
    Mauro Silvestrini
    [J]. Journal of Neurology, 2017, 264 : 2325 - 2329
12345